Workshop 15
Antiviral therapy and resistance

Programme

• 08:30 – 08:45 12 Min. 3 Min.

  • Abstract Talk
  • O 079

  An amyloidogenic fragment of human alpha-hemoglobin with combined antibacterial and antiviral activity

  • Lia-Raluca Olari (Ulm / DE)

   Antiviral therapy and resistance, Innate immunity
• 08:45 – 09:00 12 Min. 3 Min.

  • Abstract Talk
  • O 080

  Cotreatment with Influenza inhibitors and recombinant IFNα as a potential strategy to prevent emergence of drug resistance against direct-acting antivirals

  • Sriram Kumar (Muenster / DE)

   Antiviral therapy and resistance, Innate immunity
• 09:00 – 09:15 12 Min. 3 Min.

  • Abstract Talk
  • O 081

  Targeted protein degradation – development of a novel antiviral strategy by forced protein-protein interaction

  • Christopher Veeck (Marburg / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• 09:15 – 09:30 12 Min. 3 Min.

  • Abstract Talk
  • O 082

  Pharmacological inhibition of bromodomain and extra-terminal proteins induces NRF-2-mediated inhibition of SARS-CoV-2 replication and is subject to viral antagonism

  • Prof. Dr. Christine Goffinet (Berlin / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• 09:30 – 09:45 12 Min. 3 Min.

  • Abstract Talk
  • O 083

  The selective TRPML2 agonist ML2-SA1 impairs Zika virus infection in vitro

  • Kerstin Karina Schwickert (Langen / DE)

   Antiviral therapy and resistance, Host cell factors and modulation
• 09:45 – 10:00 12 Min. 3 Min.

  • Abstract Talk
  • O 084

  Selective small molecules directed to nuclear receptor RORγ isoform 1 exhibit a broad antiviral potential through metabolic restriction of virus replication

  • Dr. Friedrich Hahn (Erlangen / DE)

   Antiviral therapy and resistance, Host cell factors and modulation